1-4 of 4
Anila Qureshi
Close
Sort by
Journal Articles

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Anthony Tolcher, Thomas Julian, Anila Qureshi
Journal: Blood
Blood (2007) 110 (11): 4724.
https://doi.org/10.1182/blood.V110.11.4724.4724
Published: 2007
Journal Articles

High-Dose Mitoxantrone-Based Induction Therapy in Newly-Diagnosed AML. Results of 171 Patients Treated at NYMC between 1991–2003.

Karen Seiter, MD, Delong Liu, MD, PhD, Eric Feldman, MD, Qiuhu Shi, PhD, Paul Baskind, Muhammad Arshad, MD, Anila Qureshi, MD, Tauseef Ahmed, MD
Journal: Blood
Blood (2005) 106 (11): 1859.
https://doi.org/10.1182/blood.V106.11.1859.1859
Published: 2005
Journal Articles

Phase II Study of Gemtuzumab Ozogamycin (GO) and Cytarabine (ARA-C) in Patients with High Risk MDS and AML..

Peter Kang, MD, Karen Seiter, MD, Delong Liu, MD, PhD, Muhammad Arshad, MD, Anila Qureshi, MD, John Nelson, MD, Tauseef Ahmed, MD
Journal: Blood
Blood (2004) 104 (11): 4723.
https://doi.org/10.1182/blood.V104.11.4723.4723
Published: 2004
Journal Articles

Valgancyclovir Significantly Reduced Reactivation of CMV Following Mini-Transplantation with MAP (Mitoxantrone, Ara-C, and Pentostatin) Regimen.

Anila Qureshi, MD, Karen Seiter, MD, Tauseef Ahmed, MD, John Nelson, MD, Delong Liu, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 5082.
https://doi.org/10.1182/blood.V104.11.5082.5082
Published: 2004